Investigational drug · Phase 3
CHF10196
Also called: florensocatib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bronchiectasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "CHF10196"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CHF10196", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bronchiectasis
Approved drugs for the same conditions: Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "CHF10196" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With BronchiectasisPivotal-lookingNot yet recruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07577804 · 904 participants (planned) · Start Nov 2026 · Primary completion Apr 2030
Drug: CHF10196 tablets (florensocatib); Placebo · For: Bronchiectasis
Chiesi Farmaceutici S.p.A.Industry
NCT07744386 · 24 participants (planned) · Start Oct 27, 2026 · Primary completion Dec 15, 2028
Drug: Dabigatran Etexilate; Rosuvastatin and 1 more · For: Healthy Male Volunteers
Sites: Leeds, United Kingdom
- A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male ParticipantsNot yet recruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07683793 · 18 participants (planned) · Start Oct 14, 2026 · Primary completion Dec 9, 2026
Drug: CHF10196; Pantoprazole · For: Healthy Volunteers
Sites: Leeds, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- The dipeptidyl peptidase 1 inhibition landscape in bronchiectasis and its future direction.
Chalmers JD, Jain R, O'Donnell AE, et al. · Eur Respir Rev 2026
- Symptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials.
Gao YH, Li XS, Sun XL, et al. · Cell Rep Med 2026
- Florensocatib in adults with bronchiectasis: the HOPE-BE trial protocol and baseline demographic characteristics.
Zhong NS, Cao J, Feng Y, et al. · ERJ Open Res 2026
Also in development for Bronchiectasis
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- GSK3862995BPhase 22 trials
GSK · Bronchiectasis, Pulmonary Disease, Chronic Obstructive
- CHF6333Phase 21 trial
Chiesi Farmaceutici S.p.A. · Bronchiectasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.